GSK Cervical Cancer HPV Vaccine Cervarix Reported Effective for More Than Six Years

Falls Church, VA

GlaxoSmithKline (GSK) has new data that it says shows that its experimental cervical vaccine Cervarix protects women against the four most common types of the human papillomavirus known to cause cervical cancer for nearly six and a half years.

Over this period, which is the longest for protection reported to date, Cervarix “showed 100 percent efficacy in preventing precancerous lesions due to cancer-causing virus Types 16 and 18 and also provided substantial protection against infection caused by virus Types 31 and 45,” the company said.

The data came from an extended follow-up analysis of 776 women ages 15–25 in the U.S., Canada and Brazil who had participated in an initial efficacy study of the vaccine. Nearly 100 percent of the women in the study maintained high levels of antibodies against virus Types 16 and 18 at all times for close to six and half years, GSK said.

failure to diagnose cervical cancer malpractice lawsuits

 Subscribe to Cervical Cancer News Information Links